CNR Institutional Research Information System

AZZOLINA, ANTONINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.549
NA - Nord America 1.084
EU - Europa 396
SA - Sud America 307
Continente sconosciuto - Info sul continente non disponibili 34
AF - Africa 31
OC - Oceania 2
Totale 3.403
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.013
SG - Singapore 625
CN - Cina 356
BR - Brasile 234
HK - Hong Kong 211
VN - Vietnam 145
IT - Italia 104
NL - Olanda 98
FR - Francia 83
KR - Corea 50
IN - India 36
CA - Canada 34
GB - Regno Unito 34
JP - Giappone 32
BD - Bangladesh 31
AR - Argentina 29
DE - Germania 17
MX - Messico 15
CO - Colombia 14
EC - Ecuador 14
ID - Indonesia 12
ZA - Sudafrica 10
ES - Italia 9
FI - Finlandia 9
IL - Israele 7
KE - Kenya 7
IQ - Iraq 6
JM - Giamaica 6
RU - Federazione Russa 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
TR - Turchia 5
EG - Egitto 4
LT - Lituania 4
PH - Filippine 4
SA - Arabia Saudita 4
SE - Svezia 4
UY - Uruguay 4
AZ - Azerbaigian 3
IE - Irlanda 3
MA - Marocco 3
PE - Perù 3
PL - Polonia 3
PY - Paraguay 3
UA - Ucraina 3
UZ - Uzbekistan 3
VE - Venezuela 3
BO - Bolivia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
GR - Grecia 2
GT - Guatemala 2
KZ - Kazakistan 2
LB - Libano 2
NI - Nicaragua 2
NP - Nepal 2
PK - Pakistan 2
PT - Portogallo 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CL - Cile 1
CZ - Repubblica Ceca 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MG - Madagascar 1
MK - Macedonia 1
MM - Myanmar 1
MY - Malesia 1
NO - Norvegia 1
NR - Nauru 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SV - El Salvador 1
TG - Togo 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 3.369
Salva come PNG Salva come JPEG
Città #
Santa Clara 369
Singapore 360
Hong Kong 211
Hefei 117
San Jose 107
Beijing 77
Lauterbourg 65
Ashburn 56
Ho Chi Minh City 53
Seoul 49
Hanoi 26
Tokyo 25
Los Angeles 22
São Paulo 21
New York 20
Dallas 19
Council Bluffs 15
Mumbai 14
Buffalo 12
Montreal 10
Palermo 10
Phoenix 10
Houston 9
Brasília 8
Orem 8
Portsmouth 8
Toronto 8
Atlanta 7
Brooklyn 7
Frankfurt am Main 7
Haiphong 7
Nairobi 7
Rio de Janeiro 7
Bengaluru 6
Helsinki 6
London 6
Mexico City 6
Minamishinagawa 6
Philadelphia 6
Potenza 6
Quito 6
Thái Bình 6
Biên Hòa 5
Da Nang 5
Denver 5
Düsseldorf 5
Johannesburg 5
Milan 5
San José 5
Amsterdam 4
Belo Horizonte 4
Charlotte 4
Chennai 4
Chicago 4
Kingston 4
Memphis 4
Montevideo 4
Newark 4
Salvador 4
Ankara 3
Baku 3
Bogotá 3
Cagliari 3
Camaçari 3
City of London 3
Columbia 3
Columbus 3
Dhaka 3
Dublin 3
Elk Grove Village 3
Forest City 3
Fortaleza 3
Goiânia 3
Guayaquil 3
Lappeenranta 3
Lima 3
Manaus 3
Manchester 3
Montes Claros 3
New Delhi 3
Ninh Bình 3
Poplar 3
Porto Alegre 3
Ribeirão Preto 3
Rome 3
San Francisco 3
Santo André 3
Santos 3
St Louis 3
Stockholm 3
Tampa 3
Tashkent 3
Acalanes Ridge 2
Anápolis 2
Aparecida de Goiânia 2
Aracaju 2
Augusta 2
Aversa 2
Baltimore 2
Belvidere 2
Totale 1.995
Salva come PNG Salva come JPEG
Nome #
Potential uses of olive oil secoiridoids for the prevention and treatment of cancer: A narrative review of preclinical studies 102
Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation 92
Identification of an LPS-Induced Chemo-Attractive Peptide from Ciona robusta 92
Cationic Solid-lipid nanoparticles as DNA carriers. 84
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells 79
The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma 76
RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma 70
New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells 68
The novel NF-kB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. 65
COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. 64
Hepatocellular Carcinoma: A Difficult Cancer to Treat 63
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway 62
In vitro and in vivo antitumor activity of the proteasome inhibitor MLN2238 in hepatocellular carcinoma cells 62
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells 59
GSK-3 in liver diseases: Friend or foe? 57
Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment 57
The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment 56
Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma 54
Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells. 53
Development of nimesulide loaded solid lipid nanoparticles. 51
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells 50
Emerging Use of Nanotechnology for the Treatment of Liver Diseases 49
Cationic Solid Lipid Nanoparticles as Non Viral Vectors for the Inhibition of Hepatocellular Carcinoma Growth by RNA Interference 47
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. 44
Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma 44
Substance P selectively activates TNF-a mRNA in rat uterine immune cells: a neuroimmune link 44
Structure-based identification of a non-covalent thioredoxin reductase inhibitor with proven ADMET suitability 43
The response to simulated hypogravity is dependent on the proliferation state and temperature in FRTL-5 thyroid cells 42
Antitumor effects of DHMEQ, a novel NF-kB inhibitor, in human liver cancer cells is mediated through a reactive oxygen species-dependent mechanism. 42
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. 41
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. 40
Evidence that brain mast cells can modulate neuroinflammatory responses by tumour necrosis factor-a production 39
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 39
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 39
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. 39
Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery 38
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells 38
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 37
Cationic solid-lipid nanoparticles for gene delivery. 37
From targets to targeted therapies in Hepatocellular carcinoma 36
Molecular mechanisms of sorafenib action in liver cancer cells. 36
Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation 35
Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies 35
The novel NF-kB inhibitor DHMEQ suppresses the growth of human hepatic cancer cells through redox-dependent signaling. 35
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells. 35
Microgravity and cellular homeostasis: effects of simulated hypogravity on FRTL-5 thyroid cells. 35
Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells. 34
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 34
Combination of DHMEQ and Celecoxib synergistically exert anti-tumoral effects in human hepatoma cells. 34
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 33
Gene expression profiling of human liver cancer cells following celecoxib treatment. 32
G. Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 32
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells 32
INVOLVEMENT OF p38 AND JNK mapks PATHWAYS IN SUBSTANCE P-INDUCED PRODUCTION OF TNF - BY PERITONEAL MAST CELLS 32
DHMEQ, a novel NF-kb inhibitor, anticancer activity through induction of reactive oxygen species-dependent mechanism in human hepatoma cells. 31
Inhibition of MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells. 30
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle. 30
The multikinase inhibitor Sorafenib exhibits a strong cytotoxic effect in liver cancer cells through a MEK/ERK signaling-independent mechanism 30
Substance P induces TNF-alpha and IL-6 production through NFkB in peritoneal mast cells 30
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells. 30
Solid-lipid nanoparticles for gene delivery to cells. 30
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells 29
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells. 29
DHMEQ and Celecoxib synergistically exert anti-tumoral activities in human liver cancer cells. 29
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells. 29
Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells 28
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 28
Growth suppression and apoptosis induction in human hepatoma cells by DHMEQ, a novel NF-KB inhibitor, is mediated through a ROS-dependent mechanism. 27
Inhibition of MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells. 27
Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells 26
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells 25
Microgravity and cellular homeostasis:effects of stimulated hypogravity on FRTL-5 thyroid cells. 25
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells 25
Substance P induces TNF-α and IL-6 production through NFκB in peritoneal mast cells 24
The selective COX-1 inhibitor SC-560 suppresses cell growth and induces apoptosis in human hepatocellular carcinoma cells 24
DHMEQ, a novel NF-kb inhibitor, anticancer activity through induction of reactive oxygen species-dependent mechanism in human hepatoma cells. 24
Solid lipid nanoparticles (SLNs) containing nimesulide: preparation, characterization and in cytotoxicity studies 23
The selective COX-1 inhibitor SC-560 suppresses cell growth and induces apoptosis in human hepatocellular carcinoma cells. 22
Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies. 22
Synthesis and characterization of polyaminoacidic polycations for gene delivery. 22
Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism 18
Involvement of p38 and JNK MAPKs pathways in substance P-induced production of TNF-α by peritoneal mast cells 18
Totale 3.403
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.480
article - articoli 6.796
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 349
Totale 18.625
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20248 0 0 0 0 0 0 0 0 0 0 4 4
2024/20251.227 8 5 81 48 301 68 8 82 29 116 275 206
2025/20261.820 126 192 182 307 309 58 218 138 125 84 44 37
2026/2027348 76 94 178 0 0 0 0 0 0 0 0 0
Totale 3.403